Sanofi-Aventis acquires option to in-license infectious disease antibody
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis is to pay Alopexx Pharmaceuticals up to $375 million for the licence to a monoclonal antibody for the treatment of certain antibiotic-resistant infections.